Characterization of the protective capability of a recombinant coxsackievirus B3 variant expressing interferon-γ

Viral Immunology

Volumn 21, Issue 1, 2008, Pages 38-48

  Henke, Andreas ^a   Jarasch, Nadine ^a   Martin, Ulrike ^a   Zell, Roland ^a   Wutzler, Peter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS; IMMUNE RESPONSE; INFECTION PREVENTION; MALE; MYOCARDITIS; NONHUMAN; PROTECTION; PROTEIN EXPRESSION; VIRUS CHARACTERIZATION; VIRUS INFECTION; VIRUS RECOMBINANT;

ANIMALS; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; PANCREAS; SERUM; SPLEEN; SURVIVAL ANALYSIS; VIRAL VACCINES;

COXSACKIEVIRUS; ENTEROVIRUS; MURINAE;

EID: 41349122291     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2007.0077     Document Type: Article

References (34)

1. Chapman NM, Kim KS, Tracy S, et al.: Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice. J Virol 2000;74:7952-7962.
2. Chomczynski P, and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
3. Delman KA, Bennett JJ, Zager JS, et al.: Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 2000;11:2465-2472.
4. Donahue JM, Mullen JT, and Tanabe KK: Viral oncolysis. Surg Oncol Clin North Am 2002;11:661-680.
5. Drescher KM, Kono K, Bopegamage S, Carson SD, and Tracy S: Coxsackievirus B3 infection and type 1 diabetes development in NOD mice: Insulitis determines susceptibility of pancreatic islets to virus infection. Virology 2004;329:381-394.
6. Fohlman J, Ilback NG, Friman G, and Morein B: Vaccination of Balb/c mice against enteroviral mediated myocarditis. Vaccine 1990;8:381-384.
7. Fohlman J, Pauksen K, Morein B, Bjare U, Ilback NG, and Friman G: High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand J Infect Dis Suppl 1993;88:103-108.
8. Gravanis MB, and Sternby NH: Incidence of myocarditis. A 10-year autopsy study from Malmo, Sweden. Arch Pathol Lab Med 1991;115:390-392.
9. Henke A, Launhardt H, Klement K, Stelzner A, Zell R, and Munder T: Apoptosis in coxsackievirus B3-caused diseases: Interaction between the capsid protein VP2 and the proapoptotic protein siva. J Virol 2000;74:4284-4290.
10. Henke A, Wagner E, Whitton JL, Zell R, and Stelzner A: Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization. J Virol 1998;72:8327-8331.
11. Henke A, Zell R, Ehrlich G, and Stelzner A: Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis. J Virol 2001;75:8187-8194.
12. Henke A, Zell R, Martin U, and Stelzner A: Direct interferon-gamma- mediated protection caused by a recombinant coxsackievirus B3. Virology 2003;315:335-344.
13. Henke A, Zell R, and Stelzner A: DNA vaccine-mediated immune responses in coxsackie virus B3-infected mice. Antiviral Res 2001;49:49-54.
14. Hyoty H, and Taylor KW: The role of viruses in human diabetes. Diabetologia 2002;45:1353-1361.
15. Ikeda K, Ichikawa T, Wakimoto H, et al: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999;5:881-887.
16. Jarasch N, Martin U, Kamphausen E, Zell R, Wutzler P, and Henke A: Interferon-gamma-induced activation of nitric oxide-mediated antiviral activity of macrophages caused by a recombinant coxsackievirus B3. Viral Immunol 2005;18:355-364.
17. Jun HS, and Yoon JW: A new look at viruses in type 1 diabetes. Diabetes Metab Res Rev 2003;19:8-31.
18. Kandolf R, Ameis D, Kirschner P, Canu A, and Hofschneider PH: In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: An approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA 1987;84:6272-6276.
19. Kandolf R, Sauter M, Aepinus C, Schnorr JJ, Selinka HC, and Klingel K: Mechanisms and consequences of enterovirus persistence in cardiac myocytes and cells of the immune system. Virus Res 1999;62:149-158.
20. Kim KS, Hufnagel G, Chapman NM, and Tracy S: The group B coxsackieviruses and myocarditis. Rev Med Virol 2001;11:355-368.
21. Knowlton KU, Jeon ES, Berkley N, Wessely R, and Huber S: A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J Virol 1996;70:7811-7818.
22. Lindberg AM, Crowell RL, Zell R, Kandolf R, and Pettersson U: Mapping of the RD phenotype of the Nancy strain of coxsackievirus B3. Virus Res 1992;24:187-196.
23. Mastrangelo MJ, Maguire HC Jr., Eisenlohr LC, et al.: Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999;6:409-422.
24. Mukherjee S, Haenel T, Himbeck R, et al.: Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 2000;7:663-670.
25. Mullen JT, and Tanabe KK: Viral oncolysis. Oncologist 2002;7:106-119.
26. Ramsingh AI: Coxsackieviruses and pancreatitis. Front Biosci 1997;2:e53-e62.
27. Sin JI, Sung JH, Suh YS, Lee AH, Chung JH, and Sung YX: Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: Effect of co-injection with a granulocyte-macrophage colony stimulating factor gene. Vaccine 1997;15:1827-1833.
28. Slifka MK, Pagarigan R, Mena I, Feuer R, and Whitton JL: Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J Virol 2001;75:2377-2387.
29. Toniolo A, Falcone V, Bernasconi C, Basolo F, Speziale P, and Onodera T: DNA immunization of mice against the VP1 capsid protein of coxsackievirus B4. Scand J Immunol 2002;56:448-455.
30. Torfason EG, Reimer CB, and Keyserling HL: Subclass restriction of human enterovirus antibodies. J Clin Microbiol 1987;25:1376-1379.
31. Tracy S, Hofling K, Pirruccello S, Lane PH, Reyna SM, and Gauntt CJ: Group B coxsackievirus myocarditis and pancreatitis: Connection between viral virulence phenotypes in mice. J Med Virol 2000;62:70-81.
32. Verstrepen WA, Kuhn S, Kockx MM, Van De Vyvere ME, and Mertens AH: Rapid detection of enterovirus RNA in cerebrospinal fluid specimens with a novel single-tube real-time reverse transcription-PCR assay. J Clin Microbiol 2001;39:4093-4096.
33. Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, and Tanabe KK: An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 2000;14:301-311.
34. Zhang H, Morgan-Capner P, Latif N, Pandolfino YA, Fan W, Dunn MJ, and Archard LC: Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain. Am J Pathol 1997;150:2197-2207.